Why IsoRay (ISR) Stock Is Surging Today - TheStreet

NEW YORK (TheStreet) -- IsoRay  (ISR) - Get Report surged Tuesday after the company announced the world's first liquid cesium-131 treatment for metastatic brain cancer.

IsoRay reported the treatment of a brain tumor that had metastasized from esophageal cancer with the company's liquid Cesium-131, also called Cesitrex, which recently received FDA clearance for internal radiation therapy. The treatment used GliaSite radiation therapy Balloon Catheter System, which delivers a high dose of radiation to an area and minimizes radiation exposure to healthy brain tissue.

The stock was up 10.12% to $2.94 at 10:36 a.m. on Tuesday.

Must Read: Warren Buffett's 25 Favorite Stocks

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Image placeholder title

ISR data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.